Dr. Jason Luke, Director of Cancer Immunotherapeutic Center at UPMC Hillman Cancer Center and Kyleigh LiPira, CEO of the Melanoma Research Foundation (MRF): First-of-its-Kind Dual Immunotherapy Treatment for Advanced Melanoma Patients

Skin cancer remains the most common cancer in the U.S. despite preventative sun care measures like sunscreen use and UV-protective clothing. Fortunately, scientific advances have helped bring hope to patients facing advanced melanoma. Dr. Jason Luke, Director of Cancer Immunotherapeutic Center at UPMC Hillman Cancer Center, and Kyleigh LiPira, Melanoma Research Foundation, First-of-its-Kind Dual immunotherapy treatment for advanced melanoma patients talk about a new treatment option and what it may mean for patients facing the disease.